Lv1
50 积分 2021-07-24 加入
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
2个月前
已完结
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
2个月前
已完结
Diagnosis and Treatment of Metastatic Colorectal Cancer
2个月前
已完结
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
3个月前
已完结
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
6个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
7个月前
已完结
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
7个月前
已完结
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
8个月前
已完结
Risk factors of cytokine release syndrome: stress, catecholamines, and beyond
8个月前
已完结
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study
9个月前
已完结
皖公网安备34019202002308
